Overview
Hester Biosciences Limited is a leading animal healthcare company in India, specializing in poultry and large animal vaccines. Its strategic focus on biotechnology is highlighted by the recent approval of the H9N2 Avian Influenza vaccine, expanding its poultry vaccine portfolio. The company has successfully doubled its drug product capacity with the new fill/finish facility, supporting increased manufacturing capabilities. Hester's strategic shift aims to reduce dependence on tender-driven revenues, focusing on direct engagement with commercial markets. The company continues to invest in operational discipline, resulting in substantial improvements in profitability.
- Sector
Pharmaceuticals & Biotechnology
- Industry
Pharmaceuticals
- Market Cap
1,661 Cr
- Volatility
Low Risk
- P/E Ratio
29.9
- Industry P/E
34.1
- PEG Ratio
0.9
- P/B Ratio
4.6
- 52W High
2,347.70
- 52W Low
1,250.95
Financial Ratios
Sales CAGR
- 1Y
- 2.15%
- 3Y
- 9.31%
- 5Y
- 11.08%
- 10Y
- 12.04%
Profit CAGR
- 1Y
- 36.18%
- 3Y
- -6.95%
- 5Y
- 0.39%
- 10Y
- 5.77%
ROE
- TTM
- 15.45%
- 3Y
- 7.95%
- 5Y
- 10.32%
- 10Y
- 13.07%
ROCE
- TTM
- 14.34%
- 3Y
- 9.55%
- 5Y
- 11.06%
- 10Y
- 13.85%
Peers
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
803.05 | 1,787 Cr | 58.62 | 5.51 | 0.00 | 9.40 | 12.54 | 6.34 | ||
2714.85 | 1,678 Cr | 34.92 | 5.10 | 0.06 | 14.62 | 15.37 | 8.81 | ||
813.45 | 1,675 Cr | 25.20 | 2.88 | 0.79 | 11.44 | 14.90 | 7.32 | ||
1969.75 | 1,661 Cr | 29.85 | 4.61 | 0.56 | 15.45 | 14.34 | 8.48 | ||
562.65 | 1,627 Cr | 28.09 | 4.39 | 0.87 | 17.42 | 23.31 | 11.38 | ||
1476.00 | 1,496 Cr | 36.06 | 6.11 | 0.00 | 16.95 | 17.46 | 8.37 | ||
208.80 | 1,379 Cr | 32.02 | 5.00 | 1.94 | 15.60 | 20.59 | 13.60 | ||
| Median: 7 Co. | — | 813.45 | 1,661 Cr | 32.02 | 5.00 | 0.56 | 15.45 | 15.37 | 8.48 |
Price Chart Comparison
Documents
Investor Presentation
Q4 FY26
Actions
AI Mode
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Ask AI
